On May 16, 2024, the CDE's official website announced that the Application would be reviewed via the priority review and approval process. This marks the fourth sac-TMT indication to go through the ...

In the battle against cervical cancer, every footstep matters. This May, they are taken with a purpose. As part of the ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) has provided an update. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion's collaborator, MSD, expands clinical development program for opevesostat to women's cancers Orion's collaborator, ...

ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, announces it has raised USD ...

LAS VEGAS, NV / ACCESS Newswire / May 8, 2025 / Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac ...

In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as a novel target in lysosomal storage diseases Amsterdam, the Netherlands, May 07, 2025 ...

underperformed due to negativity around the funding environment for biopharmaceuticals and biotech research given recent federal funding cuts and a weak venture capital funding environment.